Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Pholedrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A2 known ✓ | Q05940 | 1/20 | 0.53 |
| ▸ | SLC6A2 known ✓ | P23975 | 2/20 | 0.48 |
| ▸ | ADRB2 known ✓ | P07550 | 4/20 | 0.45 |
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.45 |
| ▸ | ADRB3 known ✓ | P13945 | 1/20 | 0.45 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.45 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.45 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pholedrine SCHEMBL1649743 | 1.00 | TAAR1 (0.53) | TAAR1SIGMAR1SLC18A2SLC6A4CYP3A4 | |
| Pholedrine SCHEMBL15286090 | 0.91 | TAAR1 (0.63) | TAAR1SIGMAR1SLC18A2SLC6A4CYP3A4 | |
| Pholedrine SCHEMBL2739157 | 0.91 | TAAR1 (0.63) | TAAR1SIGMAR1SLC18A2SLC6A4CYP3A4 | |
| Pholedrine SCHEMBL119262 | 0.91 | TAAR1 (0.63) | TAAR1SIGMAR1SLC18A2SLC6A4CYP3A4 | |
| Methamphetamine SCHEMBL712603 | 0.84 | SIGMAR1 (0.78) | TAAR1SIGMAR1SLC18A2SLC6A4ALDH1A1 | |
| Methamphetamine SCHEMBL712605 | 0.84 | SIGMAR1 (0.78) | TAAR1SIGMAR1SLC18A2SLC6A4ALDH1A1 | |
| Levmetamfetamine SCHEMBL712604 | 0.84 | SIGMAR1 (0.78) | TAAR1SIGMAR1SLC18A2SLC6A4ALDH1A1 | |
| Methamphetamine SCHEMBL28548051 | 0.80 | SIGMAR1 (0.78) | TAAR1SIGMAR1SLC18A2SLC6A4 | |
| Hydroxyamphetamine SCHEMBL28341059 | 0.78 | TAAR1 (0.81) | TAAR1SIGMAR1SLC6A4SLC6A2ESR1 | |
| SCHEMBL2958028 | 0.75 | SLC6A4 (0.63) | TAAR1SIGMAR1SLC6A4CYP3A4HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1993741-B1 | INLINE APPLICATION OF COATINGS | COOK MEDICAL TECHNOLOGIES LLC (US) | 2014-03-19 | — | — | EP | disclosed |
| US-8523937-B2 | Controlled drug delivery using a zein layer modified with levulinic acid | COOK MEDICAL TECHNOLOGIES LLC (US) | 2013-09-03 | — | — | US | disclosed |
| US-8303648-B2 | Artificial venous valve containing therapeutic agent | COOK MEDICAL TECHNOLOGIES LLC (US) | 2012-11-06 | — | — | US | disclosed |
| US-8092819-B2 | Implantable medical device coated with a bioactive agent | Cook Medical Technologies LLC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-8024851-B2 | Method of producing a radially expandable prosthesis | COOK MEDICAL TECHNOLOGIES LLC (US) | 2011-09-27 | — | — | US | disclosed |
| US-7914841-B2 | Inline application of coatings | COOK MEDICAL TECHNOLOGIES LLC (US) | 2011-03-29 | — | — | US | disclosed |
| EP-1981560-B1 | ZEIN COATED MEDICAL DEVICE | MED INST INC (US) | 2010-09-08 | — | — | EP | disclosed |
| US-20090258050-A1 | Controlled Drug Delivery Using a Zein Layer Modified with Levulinic Acid | MED INSTITUTE, INC. (US) | 2009-10-15 | — | — | US | disclosed |
| EP-1993626-A2 | IMPLANTABLE MEDICAL DEVICE COATED WITH BIOACTIVE AGENT | Med Institute, Inc. (US) | 2008-11-26 | — | — | EP | disclosed |
| US-20080178459-A1 | METHOD OF PRODUCING A RADIALLY EXPANDABLE PROSTHESIS | COOK INCORPORATED (US) | 2008-07-31 | — | — | US | disclosed |
| US-20070207184-A1 | Implantable medical device coated with a bioactive agent | MED INSTITUTE, INC (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070207183-A1 | Zein coated medical device | MED INSTITUTE, INC. (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070196423-A1 | Implantable medical device coatings with biodegradable elastomer and releasable therapeutic agent | MED INSTITUTE, INC. (US) | 2007-08-23 | — | — | US | disclosed |
| WO-2007089592-A2 | IMPLANTABLE MEDICAL DEVICE COATED WITH BIOACTIVE AGENT | MED INSTITUTE, INC. (US) | 2007-08-09 | — | — | WO | disclosed |
| US-20070182055-A1 | Inline application of coatings | COOK INCORPORATED (US) | 2007-08-09 | — | — | US | disclosed |
| US-20070043423-A1 | Intraluminal device with a hollow structure | MED INSTITUTE INC. (US) | 2007-02-22 | — | — | US | disclosed |
| EP-1438942-A1 | An otorhinological drug delivery device | Schering Oy (FI) | 2004-07-21 | — | — | EP | disclosed |
| US-5840335-A | SHELL COMPRISED OF WATER INSOLUBLE WALL PERMEABLE TO PASSAGE OF EXTERNAL FLUID SURROUNDING CORE COMPRISED OF WATER SOLUBLE ACTIVE AGENT AND SOLUBLE POLYMERIC ADJUVANT CAPABLE OF UNLIMITED SWELLING | Wenzel, Prof. Dr. Udo (DE) | 1998-11-24 | — | — | US | disclosed |
| EP-0381181-B1 | A system for the controlled release of active agents and a process for its preparation | INT PHARMA AGENTUR (DE) | 1995-08-09 | — | — | EP | disclosed |
| EP-0381181-A2 | A system for the controlled release of active agents and a process for its preparation | IPA INTERNATIONALE PHARMA AGENTUR GMBH (DE) | 1990-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258050-A1 | Controlled Drug Delivery Using a Zein Layer Modified with Levulinic Acid | LTN1, LOXL2, LOXL1 | SLC18A2 316/4885SLC6A2 2718/4885ADRB2 3064/4885 |
| US-20070207183-A1 | Zein coated medical device | PCSK9, ZYX, ZFX | SLC18A2 2423/4885SLC6A2 2846/4885ADRB2 2107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.